Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Ziltivekimab?
Ziltivekimab is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Inflammation. According to Globaldata,...
Data Insights
Ziltivekimab by Novo Nordisk for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to...